Dr. Scott Klakamp is a Distinguished Research Fellow at Coherus Biosciences. Previously, he was the Senior Director and Head of Biophysics for biologics at Janssen R&D, LLC. He is also the Founder and Principal Consultant of SKD Consulting LLC. Prior to starting his own consulting company, Dr. Klakamp was the Vice President of Chemistry and Biochemistry at BiOptix Inc., a company that provided the 404pi biosensor. Previous to BiOptix, he was a Senior Research Fellow at Takeda San Francisco, Inc. where he led the Biophysical Chemistry Group. Dr. Klakamp has extensive experience in research and development involving the biophysical and analytical characterization of biologics and monoclonal antibodies.
Dr. Klakamp is one of the leading scientists in utilizing Biacore, BiOptix, KinExA, and FACS techniques to measure the binding kinetics and equilibrium dissociation constants of human monoclonal antibody/antigen complexes. He also served as a Principal Scientist II at AstraZeneca R&D Hayward (merged with MedImmune, Inc), where he led the Biophysical Chemistry Group prior to joining Takeda San Francisco. Prior to AstraZeneca, he headed the Biophysical Group at Abgenix, Inc. (acquired by Amgen, Inc.) from 2001-2006, and previously held scientific positions at Chiron, Inc., GeneMedicine, Inc, and the Pennsylvania State Police.
Dr. Klakamp has been an author on over 30 research and review papers, book chapters, and patents, and has been an invited speaker at numerous international and national meetings, and has co-edited two books. He received his B.A. in Chemistry from Houghton College and his Ph.D. in Chemistry at the Pennsylvania State University. From 1990 to 1993, he completed a postdoctoral fellowship (funded by a National Research Service Award from the National Institutes of Health) at the California Institute of Technology in bioinorganic chemistry.
